Medical News Today -
18 Sep 2013 11:00
Targeted cancer therapies - drugs that kill cancer cells with certain "driver oncogenes" - shrink tumors and extend patient survival. Ultimately though, the cancers become resistant to the targeted therapies. "Unfortunately, virtually all patients with metastatic cancer develop disease progression, limiting the effectiveness of these agents," said William Pao, M.D., Ph.D., director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center. Now, Pao and colleagues including Zh...
Share this Article